dx 8951 has been researched along with Cancer of Ovary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM; Tohgo, A; van Hattum, AH | 1 |
| Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH | 1 |
| Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M | 1 |
| Adams, M; Atkinson, R; Boven, E; Calvert, AH; Cervantes, A; Cheverton, P; Clamp, A; Ganesan, T; Jayson, GC; Lotz, J; Vasey, P | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J | 1 |
1 review(s) available for dx 8951 and Cancer of Ovary
| Article | Year |
|---|---|
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
3 trial(s) available for dx 8951 and Cancer of Ovary
| Article | Year |
|---|---|
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan | 2004 |
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Topoisomerase I Inhibitors | 2004 |
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan | 2000 |
3 other study(ies) available for dx 8951 and Cancer of Ovary
| Article | Year |
|---|---|
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Sulfhydryl Reagents; Tetraspanin 29; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Xenograft Model Antitumor Assays | 2002 |
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
New analogues of camptothecins. Activity and resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |